--(BUSINESS WIRE)--Genentech ... The CENTERSTONE study [NCT03969212] was a global Phase III trial investigating the efficacy of single-dose Xofluza, taken within 48 hours of symptoms onset ...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals ... this investigational therapy.” RP-A501 Phase 2 Pivotal Trial Overview The global, single-arm, multi-center Phase 2 pivotal trial ...